BioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant.
BioCorRx’s recovery program consists of a long-lasting implant that delivers an opioid antagonist, naltrexone, which reduces physical cravings for alcohol and opioids. The recovery service also has a counseling program specifically designed to treat alcohol and substance abuse addictions in people receiving long-term naltrexone therapy.
The Virtual Reality Medical Center said it plans to conduct studies at its office in the Scripps Memorial Hospital Campus and pursue additional grant funding from the National Institutes of Health to support more work related to BioCorRx’s implant.
“We are honored to be working with such highly respected doctors at Scripps Memorial Hospital, a premier medical facility. They will be helping us set up and conduct the study on our naltrexone implant and recovery program for alcohol and opioid addictions with the goal of validating the program’s effectiveness to the broader medical community,” BioCorRx’s president, CEO & director Brady Granier said in prepared remarks. “We believe that by conducting this study, we will gain even more 3rd-party support for our program which has already helped countless individuals over the years. Not only can this study be helpful for educating practitioners, but it may also help lay the foundation for broader national awareness and reimbursement. They will also be assisting us with grant submissions, which could support future research on our naltrexone products. Dr. Shurman is also a valuable addition to our team. Not only is he going to assist Drs. Mark and Brenda Wiederhold with the studies, but he will provide key introductions to potential strategic partners and healthcare professionals in the pain management and addiction fields.”
“We are pleased to work with BioCorRx in developing strategies to combat an issue that has become a national priority,” Dr. Brenda Wiederhold, VRMC president, said.
“The ability to strategically combine both pharmacological and technical interventions is clearly the future to successfully addressing the crisis in opioid addiction,” VRMC CEO Dr. Mark Wiederhold added.
